OT-551
OT-551 is in phase II clinical trials for the treatment of cataracts and age-related macular degeneration.
This compound was originally discovered by Othera Pharmaceuticals (acquired by Colby Pharmaceuticals in 2012), and co-developed by National Eye Institute (NEI).
General Information
Update Date：2016-04-21
- Drug Name：
- OT-551
- Research Code：
- OT-551; CPC-551
- Trade Name：
- MOA：
- NF-κB inhibitor
- Indication：
- Age-related macular degeneration (AMD); Cataract surgery
- Status：
- Phase Ⅱ (Active)
- Company：
- Colby (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-11-17
|
Molecular Weight | 277.79 | ||||||||||||
| Formula | C13H23NO3 • HCl | |||||||||||||
| CAS No. |
627085-15-8 (OT-551 Hydrochloride); 627085-11-4 (OT-551); |
|||||||||||||
| Chemical Name | Cyclopropanecarboxylic acid, 1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl ester, hydrochloride (1:1) | |||||||||||||
| OT-551 Hydrochloride （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||